Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Hepatology. 2021 Dec 17;75(3):541–549. doi: 10.1002/hep.32185

Table 2:

Biomarker performance (and 95% bootstrap confidence intervals) using established thresholds

Any Stage HCC Early-Stage HCC
Any time prior to HCC 0-6 months prior to HCC Any time prior to HCC 0-6 months prior to HCC
GALAD
(−0.63)		 Patient-level Sensitivity 57.1 (41.9-72.4) 72.0 (53.8-89.3) 53.8 (33.3-73.3) 73.7 (52.6-93.3)
Screening-level specificity 86.5 (83.0 – 89.9)
HES Algorithm
(10.17)		 Patient-level Sensitivity 45.2 (30.4-60.0) 44.0 (23.8-62.5) 34.6 (15.4-54.2) 42.1 (19.0-66.7)
Screening-level specificity 90.5(87.7 – 93.1)
AFP
20 ng/mL		 Patient-level Sensitivity 35.7 (21.7-51.4) 48.0 (28.0-68.8) 46.2 (26.1-65.4) 57.9 (33.3-80.0)
Screening-level specificity 91.7 (88.9 – 94.3)
AFP-L3%
10%		 Patient-level Sensitivity 66.7 (52.0-81.3) 72.0 (52.4-88.9) 73.1 (54.2-88.9) 73.7 (52.4-93.3)
Screening-level specificity 82.7 (78.5 – 86.5)
DCP
7.5 ng/mL		 Patient-level Sensitivity 23.8 (11.6-37.5) 20.0 (5.0-37.5) 30.8 (13.6-50.0) 26.3 (6.7-48.5)
Screening-level specificity 92.3 (89.8 – 94.6)